CK Life Sciences Int'l. (Holdings) Inc. filed its Monthly Return for the period ended 31 March 2026, confirming that both authorised and issued share capital remained static during the month.

• Authorised share capital stood at 15.00 billion ordinary shares with a par value of HKD 0.10, equivalent to HKD 1.50 billion. No increase or decrease was recorded.

• Issued share capital totalled 9.61 billion ordinary shares, unchanged from the previous month. The company held no treasury shares.

• No movements were reported under share option schemes, warrants, convertibles, or other share-related arrangements.

• CK Life Sciences confirmed compliance with the Main Board’s minimum public-float requirement, maintaining at least 25% of issued shares in public hands as of 31 March 2026.

The filing, signed by Company Secretary Eirene Yeung on 2 April 2026, indicates stable capital structure and adherence to Hong Kong Listing Rule obligations during the reporting month.